Get the Stockscreener App
0.6133
7.78%
0.0373
Calcimedica Inc stock is traded at $0.6133, with a volume of 93,428.
It is up +7.78% in the last 24 hours and up +12.46% over the past month.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
See More
Previous Close:
$0.576
Open:
$0.5852
24h Volume:
93,428
Relative Volume:
0.08
Market Cap:
$10.07M
Revenue:
-
Net Income/Loss:
$-29.56M
P/E Ratio:
-0.3115
EPS:
-1.9688
Net Cash Flow:
$-21.21M
1W Performance:
-15.82%
1M Performance:
+12.46%
6M Performance:
-79.84%
1Y Performance:
-68.80%
1-Day Range:
$0.5779
$0.64
1-Week Range:
$0.5696
$0.7253
52-Week Range:
$0.4606
$7.20
Calcimedica Inc Stock (CALC) Company Profile
Name
Calcimedica Inc
Sector
Industry
Phone
858-952-5500
Address
505 COAST BOULEVARD SOUTH, LA JOLLA
Compare CALC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CALC
Calcimedica Inc
|
0.6399 | 9.07M | 0 | -29.56M | -21.21M | -1.9688 |
VRTX
Vertex Pharmaceuticals Inc
|
455.52 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.92 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.19 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.44 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.46 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Calcimedica Inc Stock (CALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
Calcimedica Inc Stock (CALC) Latest News
If You Invested $1,000 in CALCIMEDICA INC (CALC) - Stock Titan
Revenue Check: Does CalciMedica Inc meet Warren Buffetts criteria2026 Drop Watch & Detailed Earnings Play Alerts - baoquankhu1.vn
Big Picture: Does CalciMedica Inc meet Warren Buffetts criteriaShare Buyback & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
CalciMedica receives Nasdaq delisting notices for market value and bid price - Investing.com India
CalciMedica Receives Nasdaq Deficiency Notices on Listing Standards - TipRanks
CalciMedica Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
CalciMedica (NASDAQ: CALC) faces Nasdaq market value and $1 bid price breaches - Stock Titan
Analysis Recap: Can CalciMedica Inc outperform in the next rally2026 News Drivers & Fast Entry High Yield Stock Tips - baoquankhu1.vn
US Market Recap: Is CalciMedica Inc stock a smart retirement pick2026 Price Momentum & Daily Price Action Insights - baoquankhu1.vn
CALCCALCIMEDICA INC Latest Stock News & Market Updates - Stock Titan
[EFFECT] CalciMedica, Inc. SEC Filing - Stock Titan
Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), CalciMedica (CALC) - The Globe and Mail
Oppenheimer Cuts CalciMedica (NASDAQ:CALC) Price Target to $10.00 - Defense World
Aug Highlights: Can CalciMedica Inc outperform in the next rally2025 Top Gainers & Consistent Profit Trading Strategies - baoquankhu1.vn
Performance Recap: Should I set a stop loss on CalciMedica Inc2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
CalciMedica, Inc. Common Stock share price - Mint
CalciMedica (CALC) Receives Updated Analyst Rating from Oppenhei - GuruFocus
Oppenheimer Adjusts CalciMedica Price Target to $10 From $20, Maintains Outperform Rating - marketscreener.com
CalciMedica price target lowered to $10 from $20 at Oppenheimer - TipRanks
CALC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail
Calcimedica Inc files for mixed shelf of up to $125 millionSEC filing - marketscreener.com
Calcimedica Inc Files For Mixed Shelf Of Up To $125 MillionSEC Filing - TradingView
CalciMedica (NASDAQ: CALC) files shelf to offer up to $125M in securities - Stock Titan
CalciMedica, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
CalciMedica (NASDAQ: CALC) outlines Auxora pipeline, halted AKI trial and going concern risk - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CalciMedica (Nasdaq: CALC) widens 2025 loss while advancing Auxora and PAH candidate - Stock Titan
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates - PR Newswire
CalciMedica, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Retail Trends: Whats next for CalciMedica Inc stock2025 Sector Review & Technical Entry and Exit Tips - baoquankhu1.vn
CALC Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CALC SEC FilingsCALCIMEDICA INC 10-K, 10-Q, 8-K Forms - Stock Titan
Jobs Data: Is Vistagen Therapeutics Inc. stock a top pick in earnings seasonGold Moves & Reliable Intraday Trade Alerts - baoquankhu1.vn
Does CalciMedica Inc. meet Warren Buffett’s criteria2025 Stock Rankings & Weekly High Conviction Ideas - mfd.ru
CALC Should I Buy - Intellectia AI
Should I set a stop loss on CalciMedica Inc.July 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Aug Highlights: What’s the fair value of DUK.PRA stockQuarterly Trade Review & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Earnings Risk: Does CalciMedica Inc meet Warren Buffetts criteria2025 Price Momentum & Technical Pattern Recognition Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
How Is The Market Feeling About CalciMedica Inc? - Benzinga
What is CalciMedica Inc.’s book value per shareWeekly Trend Summary & AI Enhanced Trading Signals - mfd.ru
CalciMedica downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
This CalciMedica Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
CalciMedica Shares Plunge After Discontinuing Phase II AKI Study - Citeline News & Insights
CalciMedica stock downgraded to Neutral by H.C. Wainwright after trial halt - Investing.com Canada
CalciMedica’s stock drops 75% on acute kidney injury trial termination - Clinical Trials Arena
CalciMedica discontinues AKI trial following safety concerns By Investing.com - Investing.com South Africa
CALC Stock Slumped 76% On Wednesday — Here’s Why - Stocktwits
CalciMedica discontinues Phase 2 KOURAGE trial following committee recommendation By Investing.com - Investing.com Nigeria
CalciMedica Discontinues Trial, Stock Faces Volatility - intellectia.ai
Calcimedica Inc Stock (CALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):